- Home
- NCSM vs CHRS Comparison
NCSM vs CHRS Comparison
Compare NCSM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- CHRS
- Stock Information
- Founded
- NCSM 2006
- CHRS 2010
- Country
- NCSM United States
- CHRS United States
- Employees
- NCSM N/A
- CHRS N/A
- Industry
- NCSM Oilfield Services/Equipment
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCSM Energy
- CHRS Health Care
- Exchange
- NCSM Nasdaq
- CHRS Nasdaq
- Market Cap
- NCSM 76.3M
- CHRS 84.2M
- IPO Year
- NCSM 2017
- CHRS 2014
- Fundamental
- Price
- NCSM $29.94
- CHRS $0.90
- Analyst Decision
- NCSM
- CHRS Buy
- Analyst Count
- NCSM 0
- CHRS 3
- Target Price
- NCSM N/A
- CHRS $4.68
- AVG Volume (30 Days)
- NCSM 8.1K
- CHRS 1.2M
- Earning Date
- NCSM 07-30-2025
- CHRS 08-07-2025
- Dividend Yield
- NCSM N/A
- CHRS N/A
- EPS Growth
- NCSM N/A
- CHRS N/A
- EPS
- NCSM 3.27
- CHRS N/A
- Revenue
- NCSM $168,704,000.00
- CHRS $272,251,000.00
- Revenue This Year
- NCSM $7.17
- CHRS N/A
- Revenue Next Year
- NCSM $5.44
- CHRS $106.56
- P/E Ratio
- NCSM $9.17
- CHRS N/A
- Revenue Growth
- NCSM 18.16
- CHRS 19.87
- 52 Week Low
- NCSM $15.90
- CHRS $0.66
- 52 Week High
- NCSM $38.95
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NCSM 45.45
- CHRS 59.04
- Support Level
- NCSM $29.54
- CHRS $0.73
- Resistance Level
- NCSM $30.82
- CHRS $0.82
- Average True Range (ATR)
- NCSM 1.10
- CHRS 0.04
- MACD
- NCSM -0.10
- CHRS 0.02
- Stochastic Oscillator
- NCSM 23.50
- CHRS 88.02
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.